ElectroCore this week said it received FDA emergency use authorization for its gammaCore Sapphire CV to treat asthma exacerbations in known or suspected COVID-19 patients.
The gammaCore Sapphire CV is a non-invasive vagus nerve stimulation that can be used at home or in a healthcare setting to acutely treat adults with known or suspected COVID-19 who are experiencing an exacerbation of asthma-related dyspnea and reduced airflow.
“Needless to say, we are very pleased to have received this EUA, and we intend to work vigorously to make this novel therapy available to physicians treating known or suspected COVID 19 patients who are experiencing exacerbation of asthma-related breathing difficulty,” CEO Dan Goldberger said in a news release.
The EUA was issued after data from two prospective studies of VNS or nVNS to treat asthma was released by the company.
VNS for the treatment of acute asthma exacerbations showed FEV improved from baseline by a mean …